These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32218822)

  • 1. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
    Noguchi T; Sakai K; Iwahashi N; Matsuda K; Matsukawa H; Yahata T; Toujima S; Nishio K; Ino K
    Oncol Lett; 2020 Apr; 19(4):2713-2720. PubMed ID: 32218822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
    Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
    Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.
    Iwahashi N; Sakai K; Noguchi T; Yahata T; Toujima S; Nishio K; Ino K
    Oncol Lett; 2018 Nov; 16(5):6431-6436. PubMed ID: 30405780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
    Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients.
    Sharbatoghli M; Fattahi F; Aboulkheyr Es H; Akbari A; Akhavan S; Ebrahimi M; Asadi-Lari M; Totonchi M; Madjd Z
    Front Genet; 2022; 13():938985. PubMed ID: 35938032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
    Newman AM; Bratman SV; To J; Wynne JF; Eclov NC; Modlin LA; Liu CL; Neal JW; Wakelee HA; Merritt RE; Shrager JB; Loo BW; Alizadeh AA; Diehn M
    Nat Med; 2014 May; 20(5):548-54. PubMed ID: 24705333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
    Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
    Bratman SV; Newman AM; Alizadeh AA; Diehn M
    Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.
    Kim JY; Park D; Son DS; Nam SJ; Kim SW; Jung HH; Kim YJ; Park G; Park WY; Lee JE; Park YH
    Oncotarget; 2017 Oct; 8(49):86423-86434. PubMed ID: 29156805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinheiro M; Santos C; Pinto C; Escudeiro C; Bartosch C; Santos R; Brandão A; Silva J; Teixeira MR
    Front Oncol; 2021; 11():754094. PubMed ID: 34660321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.
    Przybyl J; Chabon JJ; Spans L; Ganjoo KN; Vennam S; Newman AM; Forgó E; Varma S; Zhu S; Debiec-Rychter M; Alizadeh AA; Diehn M; van de Rijn M
    Clin Cancer Res; 2018 Jun; 24(11):2688-2699. PubMed ID: 29463554
    [No Abstract]   [Full Text] [Related]  

  • 14. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Li S; Lai H; Liu J; Liu Y; Jin L; Li Y; Liu F; Gong Y; Guan Y; Yi X; Shi Q; Cai Z; Li Q; Li Y; Zhu M; Wang J; Yang Y; Wei W; Yin D; Song E; Liu Q
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
    Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
    Shah D; Wells A; Cox M; Dawravoo K; Abad J; D'Souza A; Suh G; Bayer R; Chaudhry S; Zhang Q; Cristofanilli M; Bentrem D; Chawla A
    Ann Surg; 2024 Jan; ():. PubMed ID: 38258582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
    Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.